Elizabeth Hutson, MD
Gynecology · Sparks, NVNPI 1659462208
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,375 of the $4,808 with a category attached, or 70.2%. 29 manufacturers reported payments, led by Intuitive Surgical at 37.4% of the total. Reporting peaked in 2019 at $1,967 and has fallen 84.7% since, to $301 in 2025.
Across 146 payments — averaging $32.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- AbbVie$757
- Astellas Pharma US Inc$659
- Coloplast$317
- Caldera Medical, Inc$216
- Therapeuticsmd, Inc.$133
- plus $928 from 23 others
What the payments were for
- Speaking & faculty fees$261%
- Travel & lodging$1,14924%
- Food & beverage$3,37570%
- Education$2585%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $1,798 |
| AbbVie(2 entities) | 44 | $757 |
| Astellas Pharma US Inc | 27 | $659 |
| Coloplast | 4 | $317 |
| Caldera Medical, Inc | 3 | $216 |
| Therapeuticsmd, Inc. | 8 | $133 |
| Pfizer | 7 | $120 |
| Sumitomo Pharma America, Inc. | 5 | $113 |
| Myovant Sciences Inc. | 5 | $95 |
| AMAG Pharmaceuticals, Inc. | 5 | $83 |
| Boston Scientific | 2 | $62 |
| Baxter Healthcare | 1 | $42 |
| Laborie Medical Technologies Corp. | 2 | $40 |
| Agile Therapeutics, Inc. | 2 | $33 |
| Minerva Surgical, Inc | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Mayne Pharma Commercial LLC | 2 | $31 |
| Hologic Sales And Service, LLC | 2 | $31 |
| Applied Medical Resources Corporation | 1 | $30 |
| Scynexis, Inc. | 1 | $29 |
| Merck | 1 | $25 |
| TELA Bio, Inc. | 1 | $20 |
| Biom'up France SAS | 1 | $19 |
| Roche Diagnostics Corporation | 1 | $19 |
| Amgen | 1 | $17 |
| Bayer | 1 | $16 |
| 180 Medical, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $12 |
| Lupin Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,619
- ALTIS$272
- Desara$182
How this compares
$4,808 in reported general payments places this provider in the 85th percentile of 30 gynecology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 71 | $69,223 |
| Estradiol | 518 | $29,970 |
| PremarinEstrogens, Conjugated | 33 | $16,740 |
| MyrbetriqMirabegron | 15 | $13,357 |
| EstringEstradiol | 13 | $6,665 |
| Estradiol (Twice Weekly)Estradiol | 42 | $4,651 |
| DottiEstradiol | 17 | $2,717 |
| YuvafemEstradiol | 17 | $2,690 |
| LyllanaEstradiol | 17 | $2,574 |
| ProgesteroneProgesterone, Micronized | 55 | $2,330 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 126 | $1,771 |
| Clobetasol Propionate | 57 | $1,619 |
| ValacyclovirValacyclovir Hcl | 21 | $702 |
| Fluconazole | 66 | $448 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $113 | $69,22371 claims |
| PfizerPremarin, Estring | $120 | $23,40546 claims |
| Astellas Pharma US IncMyrbetriq | $659 | $13,35715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 gynecology providers in Nevada.
Other gynecology in Sparks
- Duane AndersonLas Vegas$24K
- Randall JackReno$18K
- Yizhou ErnstReno$7K
- Barbara WotherspoonLas Vegas$5K
- Hayat JawadiHenderson$3K
- Paul DaskalosNorth Las Vegas$3K
- Sherrie HaldReno$2K
- Maribel MonroeLas Vegas$2K
- Shana MilesNellis Afb$2K
- Staci PaulReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.